We all age and, given the UK's rapidly greying population, the problems associated with age are grabbing headlines as never before. So, when Aricept, the first licensed treatment for Alzheimer's, was launched by Eisai and Pfizer in 1997, demand was expected to be massive. Aricept is effective in the earlier stages of the disease - when sufferers are forgetful rather than totally disorientated - but it offers relief rather than a lasting cure. It works by boosting levels of the chemical acetycholine in the brain, temporarily improving short-term memory and making everyday life a lot easier. A controversial early television advertising campaign caused concern in the medical establishment, particularly about Aricept's cost-effectiveness. A number of health authorities refuse to prescribe it. Sales have been modest but, as one analyst says, 'It's all there is for Alzheimer's.'
ONE MINUTE BRIEFING: Consultancy co-founder Daniele Fiandaca says he didn't really understand inclusion until he found himself the 'token man' in the room.
External oversight of your directors can save your business a lot of trouble, but many chairs are reluctant.
Thinking of setting up on your own? An MBA could be the answer.
ONE MINUTE BRIEFING: European boss Chris Hirst brought 24 of the media giant's brands into one building in an effort to create a cohesive culture.
ONE MINUTE BRIEFING: Dreams CEO Mike Logue couldn't get his new executive team to gel, so he decided to think outside the box.
CBI president and Tesco chair John Allan focuses on adaptability, proper planning and teamwork.